CHOEP versus Alternating hCHOP/IVEP for High Grade Non-Hodgkin’s Lymphomas: A Randomized Multicentre Trial
作者:
H. Köppler,
K.H. Pflüger,
I. Eschenbach,
R. Pfab,
J. Birkmann,
W. Zeller,
E.U. Steinhauer,
C. Gropp,
S. Oehl,
E. Lötzke,
H. Kuhn,
P. Drings,
H.H. Großmann,
K. Lennert,
H. Stein,
M. Khoury,
W. Heinzelmann,
K. Havemann,
期刊:
Onkologie
(Karger Available online 1991)
卷期:
Volume 14,
issue 2
页码: 181-184
ISSN:0378-584X
年代: 1991
DOI:10.1159/000216968
出版商: S. Karger GmbH
关键词: High grade non-Hodgkin’s lymphoma;Combination drug therapy;Radiotherapy;Multicentre randomized trial
数据来源: Karger
摘要:
185 patients with high grade non-Hodgkin’s lymphoma stages II-IV entered this multicentre trial and were randomized to receive either four cycles of CHOEP (cyclophosphamide 750mg/m2 i.v. d 1, dox-orubicin 50 mg/m2 i.v. d 1, vincristine 2 mg i.v. d 1, etoposide 100 mg/ m2 i.v. d 3–5, prednisolone 100 mg p.o. d 1–5) (treatment arm A), or four cycles of chemotherapy with hCHOP (cyclophosphamide 1,200 mg/m2 i.v. d 1, doxorubicin 40 mg/m2 i.v. d 1 + 2, vincristine 2mg i.v. d 1, prednisolone 100 mg p.o. d 1–5) alternating with IVEP (ifosfamide 1,500 mg/m2 i.v. d 1–5, vindesine 3 mg/m2 i.v. d 1, etoposide 120mg/m2 70 years after hCHOP. Main side effects were mild nausea/vomiting, leukopenia and fever/infection associated with leukopenia. In conclusion, both treatment modalities produced high complete remission rates. A longer follow-up will be needed to exclude differences in overall and diseas
点击下载:
PDF
(1940KB)
返 回